Skip to Main Content

Paper Details

A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
Br J Haematol
12
2022
Author NameAffiliation
Lionel Ad??sAssistance publique hopitaux de paris, and Universite de Paris Cite
Thorsten BraunHopital Avicenne Assistance publique hopitaux de paris, and Universite Paris 13
Thomas CluzeauUniversity Hospital
Claude PreudhommeLille University Hospital, Lille and INSERM UMR-S 7
  • 1 - 4

Datasets

Release 1.2